![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Mls Multimedia | ASE:MLS | Athens | Ordinary Share |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.57 | 0.565 | 0.638 | 0.00 | 01:00:00 |
RNS Number:7972P Medical Solutions PLC 16 September 2003 16 September 2003 MEDICAL SOLUTIONS ACQUIRES A SECOND LABORATORY FACILITY IN DUBAI Medical Solutions plc, ("Medical Solutions" or "the Company") the Nottingham based supplier of services for drug developers and healthcare providers announces today the acquisition of Histopathology & Specialty Laboratory (HSL) in Dubai for #275,000 in a part shares part cash transaction. In June of this year Medical Solutions acquired a private laboratory in Dubai with annual post tax profits of approximately #1million. This established the Company as a significant provider of speciality healthcare services in the region. The acquisition of HSL will provide additional histopathology capacity complementing Medical Solutions' existing laboratory in Dubai and will provide additional services for the rapidly expanding private healthcare market in the region. Both of these facilities will be transferred to Dubai Healthcare City (DHCC), the $2 billion green-field development, in July 2004.The aim of the Dubai Healthcare City initiative is to provide the highest quality healthcare services through the creation of a world class cluster of healthcare professionals and service providers. This is intended to satisfy the needs of the expanding private hospital market in Dubai, the Gulf, and its catchment area of 2 billion people in the region. Other significant healthcare providers involved in the DHCC initiative include The Harvard Medical School, The Johns Hopkins Medical Institute and The Mayo Clinic. The acquisition was made for #100,000 in cash and the transfer of #175,000 worth of ordinary shares of 2p each in the Company ("Ordinary Shares") valued at the mid price at the close of business on 11 September 2003. In addition, a cash payment of up to #75,000 cash will be payable on the achievement of agreed financial targets for the first year following the acquisition. The laboratory already has a profitable business providing services for all the major private hospitals in Dubai with a turnover of more than AED 1,300,000 (#225,000) and a profit of AED 300,000 (#52,000). Medical Solutions is acquiring equipment with HSL with a value of approximately AED 375,000 (#65,000). Application has today been made to the UK Listing Authority and the London Stock Exchange for 479,452 Ordinary Shares to be admitted to the Official List and to trading on the London Stock Exchange's main market. Admission of these Ordinary Shares is expected to become effective on 19 September 2003. Charles Green, CEO commented: "The acquisition of this specialty laboratory was a wonderful opportunity to buy a cash generative business that will support our strategic intentions to become the centre of excellence for pathology services in this rapidly growing and financially important region" Dr Samar Hourieh, Medical Director, HSL, said: "Demand in the UAE for high quality medical services is increasing rapidly and the opportunity to be part of the Medical Solutions Group providing high quality services from state of the art laboratories was very attractive." For further information, please contact: Medical Solutions Charles Green, Chief Executive Officer Andy Longstaffe, Finance Director Tel: +44 (0) 115 973 9010 Beattie Financial Mike Wort / Ann-marie Wilkinson Tel: +44 (0) 20 7398 3300 Notes to Editors Medical Solutions plc provides world leading services and technology for cancer diagnosis and pathology, supporting the Healthcare, Pharmaceutical and Biotechnology sectors. The group has two major divisions. The Services Division has a range of services including Specialist Pathology, Biomaterials Resources and Expertise, and 5 Laboratories. These services are provided to the Pharma / Biotech Industry worldwide and to Healthcare providers, both public and private. The Technology Divisions' range includes specialist imaging software for telemedicine, image analysis and quantitation, and the SurePath liquid based cytology (smear test) system. This division is also key in supporting its' Service divisions offerings to both the Drug Development market and the Healthcare market. The combination of world-renowned expertise, state of the art reference laboratory facilities and innovative imaging technology puts Medical in a unique position. This information is provided by RNS The company news service from the London Stock Exchange END ACQGUUMCBUPWUQQ
1 Year Mls Multimedia Chart |
1 Month Mls Multimedia Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions